Chancellor’s former hedge fund invested heavily in Moderna, which had 94.5% trial success
- Coronavirus – latest updates
- See all our coronavirus coverage
The chancellor, Rishi Sunak, has refused to disclose whether he will profit from a surge in the share price of the Covid-19 vaccine manufacturer Moderna, one of the biggest investments held by the hedge fund he co-founded before entering parliament.
Moderna has become the latest biotech firm to announce successful trials of its vaccine, declaring on Monday that it was 94.5% effective in trials.
